Overview


According to FutureWise analysis the market for Argatroban is expected to register a CAGR of 3.72% from 2023-2031.

Argatroban is a synthetic direct thrombin inhibitor, meaning it's a medication designed to hinder the formation and enlargement of blood clots. Thrombin, an enzyme in the bloodstream, is pivotal in clotting. Argatroban directly binds to thrombin, impeding its activity and averting clot formation. Administered intravenously under strict medical supervision, Argatroban allows precise control over anticoagulation levels. Its primary metabolism occurs in the liver, rendering it suitable for patients with compromised kidney function, as it doesn't heavily rely on renal elimination.

Due to its potent anticoagulant properties, using Argatroban necessitates vigilant monitoring of blood clotting parameters to ensure correct dosage and prevent excessive bleeding. This underscores the importance of close medical oversight for individuals receiving Argatroban. Argatroban is pivotal in anticoagulant therapy, particularly in cases where alternative options like heparin are unsuitable. Its direct inhibition of thrombin is indispensable in averting and managing thrombotic conditions. However, meticulous dosing and monitoring are imperative to balance its anticoagulant effects and the risk of bleeding.

FutureWise Market Research has published a report that provides an insightful analysis of Argatroban Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Argatroban Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • PFIZER INC
  • SANDOZ
  • GLAXOSMITHKLINE PLC
  • FRESENIUS KABI AG
  • EAGLE PHARMACEUTICALS INC
  • MITSUBISHI TANABE PHARMA
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • WEST-WARD,INC
  • MIDAS PHARMA GMBH
  • AUROBINDO PHARMA LIMITED

(Note: The list of the major players will be updated with the latest market scenario and trends)

Increased prevalence of thrombotic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and heparin-induced thrombocytopenia (HIT), is a significant driver for the Argatroban market. This has led to a higher demand for anticoagulant therapies like Argatroban. As healthcare awareness increases, there is a greater recognition and diagnosis of HIT, a condition characterized by a drop in platelet count and an increased risk of blood clot formation. Argatroban is a crucial alternative anticoagulant for patients with HIT, driving its demand.  Improvements in healthcare infrastructure and accessibility to advanced medical treatments have expanded the availability and utilization of specialized anticoagulant therapies like Argatroban.  Older individuals are more prone to thrombotic disorders, and with an aging population, there is an elevated demand for anticoagulants like Argatroban to manage these conditions effectively and hence driving the market growth.

However, the regulatory approval process for new anticoagulant drugs like Argatroban can be rigorous and time-consuming. Meeting these standards and obtaining necessary approvals can significantly challenge manufacturers.  In certain regions, access to specialized anticoagulant therapies like Argatroban may be limited due to regulatory restrictions, economic considerations, or healthcare infrastructure limitations. This can constrain the market potential in those areas.

By Product

  • Argatroban Powder
  • Argatroban Injection

By Applications

  • Heparin-induced Thrombocytopenia (HIT)
  • Percutaneous Coronary Intervention
  • Cerebral Arterial Thrombosis
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to an increase in the prevalence of peripheral artery disease and significantly impacting the usage of argatroban, robust healthcare infrastructure, the prominent presence of key industry players, a surge in chronic disease cases, and heightened research endeavors in this geographical region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Argatroban Market By Product, By Applications and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Argatroban Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Argatroban Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Argatroban Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Argatroban Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Argatroban Powder
        2. Argatroban Injection

  • 8.   Argatroban Market, By Applications Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Heparin-induced Thrombocytopenia (HIT)
        2. Percutaneous Coronary Intervention
        3. Cerebral Arterial Thrombosis
        4. Others

  • 9.   North America Argatroban Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Argatroban Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Argatroban Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Argatroban Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. PFIZER INC
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. SANDOZ
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. GLAXOSMITHKLINE PLC
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. FRESENIUS KABI AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. EAGLE PHARMACEUTICALS INC
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. MITSUBISHI TANABE PHARMA
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. TEVA PHARMACEUTICAL INDUSTRIES LTD
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. WEST-WARD,INC
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. MIDAS PHARMA GMBH
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.AUROBINDO PHARMA LIMITED
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11